NLRP3 and gout: In an open proof-of-concept phase 2a clinical trial for male gout patients, dapansutrile was first discovered to be a specific NLRP3 inflammasome inhibitor with satisfactory safety and efficacy in reducing joint pain (Klück et al., 2020).